Loading
Pyxis Oncology, Inc. Stock: price and insider trades · United States
1 insider bought shares over the last 90 days, the latest filed 02 Oct 2026.
Pyxis Oncology, Inc.: what insiders have been doing
Every trade that managers of Pyxis Oncology, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Pyxis Oncology, Inc. logged 4 filings by 4 insiders.
Open-market activity splits into 1 purchase and 1 sale totalling €1,201; 1 insider sit on the buying side and 1 insider on the selling side. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a sale of €1,201 from Humphrey Rachel, disclosed on 25 March 2026, or 0.0005% of market capitalisation. On the buying side, the filings list 1 major shareholder among the declarants.
With 4 filings in twelve months, the company is quieter than the median of 19 filings across the 5,811 companies we follow on the same exchange. Since 2021, the database holds 12 purchases and 4 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 13.9 m USD and net income at -79.6 m USD.
The most recent open-market purchase was published on 2 October 2026, 16 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€5M
12 ops. · all time
Sell Volume
€5M
4 ops. · all time
Who traded when
BuySaleGordonMD Global Investments LP1 buy
Pamela Ann Connealy1 buy
Rachel Humphrey1 sale
Since the insiders bought
- +158.2%Entry US$2.01 · Close at T+365 US$5.19
- +77.5%Entry US$2.04 · Close at T+365 US$3.62
- +125.5%Entry US$2.20 · Close at T+365 US$4.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Pyxis Oncology, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$8.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,553 of 24,148 companies
26.7
score / 100
Value7
Quality47
FCF yld-30%
Earn yld-37%
EV/EBITDA·
ROE-179%
Gross mgn83%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.80
Analyst consensus
9 analystsStrong buy
US$6.00Target US$8.67(+381%)US$19.00
Income statement
RevenueUS$13.9M
Gross profitUS$11.5M83% margin
EBITDA-US$79.9M-577% margin
Net income-US$79.6M-574.5% margin
Valuation
PER (forward)-1.6x
P/Book10.0x
Beta1.38
Balance sheet & cash
Market capUS$215M
Total debtUS$18.7M
Free Cash Flow-US$63.5M
Debt / Equity156%
Profitability & ownership
ROE-179.1%
ROA-63.0%
% insiders9.5%
% institutions39.5%
Last declaration on 2 October 2026
Declarations59 total
5,517,000 sharesCommon Stock, par value $0.001 per share ("Common Stock")SEC:0000919574-26-006609:0
Canonical exit: 30 Dec 2026 (T+90)
35,000 shares@ US$3.05810.044% mcap100.0% of flowCommonSEC144:0001959173-26-004977
109,461 shares0Common StockSEC:0001193125-26-124380:0
1,400 shares@ US$0.97270.0005% mcap100.0% of flowCommon StockSEC:0000905148-26-001434:0
5,450 shares@ US$2.009.5% of flowCommon StockSEC:0000950170-24-131606:0
Canonical exit: 24 Feb 2025 (T+90)
6,000 shares0Common StockSEC:0000950170-24-070833:0
38,741 shares0Common StockSEC:0000950170-24-038099:0
38,741 shares0Common StockSEC:0000950170-24-038102:0
35,219 shares0Common StockSEC:0000950170-24-038105:0
328,710 shares0Common StockSEC:0000950170-24-038108:0
131,484 shares0Common StockSEC:0000950170-24-038097:0
35,219 shares0Common StockSEC:0000950170-24-038103:0
35,219 shares0Common StockSEC:0000950170-24-038104:0
36,949 shares@ US$1.4042.7% of flowCommon StockSEC:0001209191-23-056969:0
40,000 shares0Common StockSEC:0001209191-23-055744:0
8,000 shares@ US$1.8712.9% of flowCommon StockSEC:0001209191-23-050734:0
Canonical exit: 27 Dec 2023 (T+90)
6,426 shares@ US$1.846810.3% of flowCommon StockSEC:0001209191-23-050685:0
Canonical exit: 26 Dec 2023 (T+90)
2,500 shares@ US$1.8726.4% of flowCommon StockSEC:0001209191-23-050686:0
Canonical exit: 26 Dec 2023 (T+90)
5,000 shares@ US$1.7749.5% of flowCommon StockSEC:0001209191-23-050495:0
Canonical exit: 24 Dec 2023 (T+90)
12,000 shares@ US$1.670317.2% of flowCommon StockSEC:0001209191-23-050492:0
Canonical exit: 24 Dec 2023 (T+90)
5,000 shares@ US$1.7397.4% of flowCommon StockSEC:0001209191-23-050432:0
Canonical exit: 21 Dec 2023 (T+90)
2,500 shares@ US$1.739724.2% of flowCommon StockSEC:0001209191-23-050433:0
Canonical exit: 21 Dec 2023 (T+90)
100 shares@ US$2.250.5% of flowCommon StockSEC:0001209191-23-049826:0
20,000 shares@ US$2.270799.5% of flowCommon StockSEC:0001209191-23-049366:0
187,793 shares0Common StockSEC:0001209191-23-048819:0
25 of 59 declarations
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (ticker: PYXS) is a U.S.-listed biotechnology company traded on the NASDAQ in the United States, and it belongs squarely in the healthcare and pharma complex. The company was founded in June 2018 and launched operations in July 2019. Its headquarters are in Boston, Massachusetts, a leading U.S. biotech cluster. From inception, Pyxis has been built around an oncology thesis focused on the tumor microenvironment, aiming to create therapies that can directly attack cancer cells while also addressing immune suppression and immune evasion. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/static-files/be1b7460-c18f-41f5-b85d-de9ec789acdd?utm_source=openai))
Pyxis Oncology’s business model is centered on a clinical-stage pipeline with an emphasis on antibody-drug conjugates (ADCs) and selected immuno-oncology programs. The company’s core approach is to deliver highly potent payloads directly to tumor tissue through targeted biologics, which may offer a more selective therapeutic profile than conventional chemotherapy. Its lead and most closely watched asset is PYX-201, a clinical-stage ADC, supported by additional programs and platform capabilities. The pipeline was broadened materially through the acquisition of Apexigen in 2023, which added antibody-generation rights and strengthened the company’s development toolkit. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-advances-pyx-106-and-pyx-201-clinical-programs?utm_source=openai))
Read moreShow less
In competitive terms, Pyxis occupies a crowded but strategically important niche: clinical-stage oncology biotech. It competes with larger pharmaceutical companies and specialist ADC/immuno-oncology players, so its differentiation depends on scientific novelty, clinical execution, and smart partnering. The company has highlighted collaboration with Merck for a clinical study combining PYX-201 with KEYTRUDA, which is a meaningful validation point for the program’s strategic relevance. Pyxis is targeting difficult solid tumors, including head and neck cancer, breast cancer, and certain sarcoma settings, where unmet medical need remains high and successful clinical data could be commercially significant. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical/?utm_source=openai))
Recent developments have remained centered on clinical progress and capital discipline. In March 2026, Pyxis reported its full-year 2025 results and stated that cash and cash equivalents were expected to fund operations into the fourth quarter of 2026. The company also indicated that additional preclinical and clinical data disclosures are expected in 2026, while management changes have supported the next phase of execution. For investors, PYXS is best viewed as a high-risk, high-upside oncology biotech: the equity case is driven by pipeline milestones, but the investment profile remains highly dependent on clinical readouts, partnering, and future financing needs. ([ir.pyxisoncology.com](https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-provides-business-update-and-reports-fourth?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
